Incidence and predictors of drug-eluting stent fracture in human coronary artery a pathologic analysis.

OBJECTIVES The aim of this study was to perform pathologic assessment on stent fracture. BACKGROUND Clinically, stent fracture has been reported in 1% to 2% of patients after drug-eluting stent (DES) implantation. METHODS High-contrast film-based radiographs of 177 consecutive lesions from the CVPath DES autopsy registry were reviewed. Stent fracture was graded as I (single-strut fracture), II (> or =2 struts), III (> or =2 struts with deformation), IV (with transection without gap), and V (with transection causing gap in stent segment). The incidence of adverse pathologic findings (thrombosis and restenosis) was assessed histologically. RESULTS Stent fracture was documented in 51 lesions (29%; grade I = 10, II = 14, III = 12, IV = 6, and V = 9). Lesions with stent fracture had longer duration after implantation (172 days [interquartile range (IQR) 31 to 630 days] vs. 44 days [IQR 7 to 270 days], p = 0.004), a higher rate of Cypher (Cordis Corp., Miami Lakes, Florida) stent usage (63% vs. 36%, p = 0.001), longer stent length (30.0 mm [IQR 22.0 to 40.0 mm] vs. 20.0 mm [IQR 14.0 to 27.3 mm], p < 0.0001), and a higher rate of overlapping stents (45% vs. 22%, p = 0.003). Although fracture with grade I to IV did not have significant impact on the occurrence of adverse pathologic findings such as thrombosis and restenosis, 67% of the grade V fracture lesions were associated with adverse pathologic findings at fracture sites. Longer stent length, use of Cypher, and longer duration of implant were identified as independent risk factors of stent fracture by logistic regression analysis. CONCLUSIONS The incidence of stent fracture was 29% lesions at autopsy, which is much higher than clinically reported. A high rate of adverse pathologic findings was observed in lesions with grade V stent fracture, whereas fracture with grade I to IV did not have a significant impact on the pathological outcome.

[1]  Gregg W. Stone,et al.  A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease , 2004 .

[2]  Renu Virmani,et al.  Morphological Predictors of Restenosis After Coronary Stenting in Humans , 2002, Circulation.

[3]  S. Allaqaband,et al.  Stent fracture, an incidental finding or a significant marker of clinical in‐stent restenosis? , 2008, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[4]  Gregg W Stone,et al.  A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. , 2004, The New England journal of medicine.

[5]  Dong-Gu Shin,et al.  Frequency of stent fracture as a cause of coronary restenosis after sirolimus-eluting stent implantation. , 2007, The American journal of cardiology.

[6]  Jeffrey W Moses,et al.  Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. , 2003, The New England journal of medicine.

[7]  G. Nakazawa,et al.  Incidence and clinical impact of coronary stent fracture after sirolimus‐eluting stent implantation , 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[8]  J. Shite,et al.  Sirolimus-eluting stent fracture with thrombus, visualization by optical coherence tomography. , 2006, European heart journal.

[9]  Neville Kukreja,et al.  Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study , 2007, The Lancet.

[10]  R. Virmani,et al.  Pathological Correlates of Late Drug-Eluting Stent Thrombosis: Strut Coverage as a Marker of Endothelialization , 2007, Circulation.

[11]  D. Kim,et al.  Clinical characteristics of stent fracture after sirolimus-eluting stent implantation. , 2009, International journal of cardiology.

[12]  J. Butany,et al.  Coronary artery stents: identification and evaluation , 2005, Journal of Clinical Pathology.

[13]  H. Izawa,et al.  Frequency, predictors and outcome of stent fracture after sirolimus-eluting stent implantation. , 2009, International journal of cardiology.

[14]  J. Forrester,et al.  Stent fracture associated with drug‐eluting stents: Clinical characteristics and implications , 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[15]  D. Leong,et al.  Very late stent fracture associated with a sirolimus-eluting stent. , 2008, Heart, lung & circulation.

[16]  Michael Joner,et al.  Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. , 2006, Journal of the American College of Cardiology.